Get started
SHANDONG LUKANG PHARMACEUTICAL COSS

SHANDONG LUKANG PHARMACEUTICAL CO

10.48CNYD
−0.40−3.68%
At close at Mar 28, 08:50 GMT
CNY
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals

600789 fundamentals

Key facts

Market capitalization‪9.42 B‬CNY
Dividend yield (indicated)1.26%
Price to earnings Ratio (TTM)24.74
Basic EPS (TTM)0.44CNY
Founded1966
Employees (FY)‪6.39 K‬
CEOKun Dong
Websitelkpc.com
About

Shandong Lukang Pharmaceutical Co., Ltd. engages in the development, production, and sale of pharmaceutical products. Its products include antibiotics, amino acids, cardiovascular and cerebrovascular, semi-synthetic antibiotics raw materials, biological drugs, infusion, proprietary Chinese medicines, pharmaceutical intermediates, animal health antibiotics, starch, and glucose. The company was founded in 1966 and is headquartered in Jining, China.

Ownership
‪‪898.67 M‬‬
Free Float shares
‪‪897.34 M‬‬ (99.85%)
Closely held shares
‪‪1.33 M‬‬ (0.15%)
Free Float shares
‪‪897.34 M‬‬ (99.85%)
Closely held shares
‪‪1.33 M‬‬ (0.15%)
Capital structure
Market cap
‪‪9.42 B‬‬
Debt
‪‪3.44 B‬‬
Minority interest
‪‪143.39 M‬‬
Cash & equivalents
‪‪773.76 M‬‬
Enterprise value
‪‪12.23 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪9.42 B‬‬
Price to earning ratio (P/E)
24.74x
Price to sales ratio (P/S)
1.58x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
24.74x
Price to sales ratio (P/S)
1.58x
Valuation ratios
‪0.00‬
‪0.40‬
‪0.80‬
‪1.20‬
‪1.60‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪7.00‬
‪14.00‬
‪21.00‬
‪28.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪3.0%‬
‪6.5%‬
‪10.0%‬
‪13.5%‬
‪17.0%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪500.00 M‬‬
‪‪1.00 B‬‬
‪‪1.50 B‬‬
‪‪2.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪400.00 M‬‬
‪‪800.00 M‬‬
‪‪1.20 B‬‬
‪‪1.60 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪400.00 M‬‬
‪‪800.00 M‬‬
‪‪1.20 B‬‬
‪‪1.60 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Veterinary Medicine
Pharmaceutical Preparations
Active Pharmaceutical Ingredient
Other
Other Business
By country
Period: 2024
China
Foreign

Dividends

Dividend yield, history and sustainability

Dividend summary
30.01%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
1.05%
Last payment
0.02
Last ex-date
Dec 18, 2024
Dividend history
‪0.55%‬
‪0.76%‬
‪0.97%‬
‪1.18%‬
‪1.39%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.04‬
‪0.07‬
‪0.11‬
‪0.14‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−1.30 B‬‬
‪0.00‬
‪‪1.30 B‬‬
‪‪2.60 B‬‬
‪‪3.90 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪1.30 B‬‬
‪‪2.60 B‬‬
‪‪3.90 B‬‬
‪‪5.20 B‬‬
Assets
Liabilities